October 1, 2015 — Infinitt North America will feature the Infinitt Healthcare Platform (IHP) at RSNA 2015. This centralized archive solution provides open, standards-based storage and manages DICOM and non-DICOM data over their life cycle regardless of where the data originated, and making it easier and more cost-efficient to comply with retention policies and security regulations. 

October 1, 2015 — The first and only system that delivers real-time X-ray radiation dose monitoring for physicians and clinicians will be featured at Radiological Society of North America (RSNA) 2015 annual meeting. The RaySafe i2 is an active dosimetry system that enables effective behavior change by showing physicians and staff their real-time dose during live procedures.

A sticky, protein-rich gel created by Johns Hopkins researchers appears to help stem cells stay on or in rat hearts and restore their metabolism after transplantation, improving cardiac function after simulated heart attacks, according to results of a new study.

September 29, 2015 — A new report from the American Heart Association (AHA) projects that the number of Americans diagnosed with heart failure (HF) will increase nearly 40 percent within 15 years, and the associated costs will nearly double. With these numbers in mind, the AHA announced the launch of the national Rise Above Heart Failure initiative.  

The Innovation Institute announced that Boston Scientific has signed an agreement to become the founding medical device sponsor of the institute’s Innovation Lab in Newport Beach, California.

New 12-month clinical trial outcomes assessing the safety and performance of the Boston Scientific Eluvia drug-eluting vascular stent system reflect a primary patency rate of more than 96 percent.

Researchers have discovered how to predict some cardiac arrhythmias several steps before they even occur. It’s a finding that could lead to an improved cardiac device, with equipment designed to detect when arrhythmias are about to occur and then act to prevent them.

The Icahn School of Medicine at Mount Sinai has launched the international TWILIGHT clinical trial to test the safety and effectiveness of treating coronary stent patients with ticagrelor alone instead of combining it with aspirin, which is the current standard of care.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now